Pfizer's Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord Injury

Links shared publicly online about this topic.

200
total visits

Pfizer's Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord Injury

Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoi

View full resource at medicalnewstoday.com

Tags: Seizure Medication, Fibromyalgia Medication, Neuropathic Pain Medication, Neuropathic Pain, Phase 3 Clinical Trial, Lyrica, Pfizer, Epilepsy Medication

Most Recently Shared on June 22, 2011 at 5:06 pm By:

MNT Pain News

Pfizer's Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord In... http://mnt.to/3Xxq

11 months ago...

Retweet

Favorite

Also Shared By:

MNT Neurology News

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

news-medical.net — “Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.” View full resource at news-medical.net